Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and collaborations with external partners. While Anthropic avoids drug discovery to not compete with its pharma clients, it recently partnered with Novo Nordisk for joint drug discovery efforts. The move highlights the company's commitment to integrating AI with practical biological testing despite ongoing industry concerns about AI risks and calls for regulation.
Novo Nordisk, which recently partnered with Anthropic for drug discovery, trades at USD 43.29 on Pluang with a slight 1-day gain of 0.22%. The stock shows strong investor interest with 72% buy orders and a dividend yield of 4.16%. These figures are current as of Sep 19, 2026 06:21 WIB.
Novo Nordisk's Phase 3 STEP Young trial demonstrated that weekly semaglutide, combined with lifestyle changes, helped many children aged 6 to under 12 reduce their body mass index below the clinical obesity threshold. Despite this success, the stock ...
Crude oil prices surged above $100 per barrel after drone attacks forced Saudi Arabia to shut its critical East-West pipeline, which carries about 4 million barrels per day to the Red Sea port of Yanbu. This pipeline outage threatens up to 4% of the ...
